Cortagen

Cortagen (also known as Ala-Glu-Asp-Pro, AEDP) is a prominently researched experimental compound classified strictly within the Khavinson Peptide framework. Operating primarily through advanced pharmacological pathways, its core mechanism of action is as follows: it synthetic tetrapeptide (Ala-Glu-Asp-Pro) Khavinson bioregulatory peptide with tissue-specific regulatory activity in cortical and peripheral nerve tissue. Penetrates cell nuclei, modulates gene expression profiles associated with neuroregeneration, and stimulates differentiation of neuronal progenitor cells. Also documented with cardioprotective effects via modulation of cardiac gene expression. with an established metabolic degradation profile, In preclinical investigative trials and independent academic studies, researchers utilizing Cortagen have documented significant, quantifiable biological outcomes, primarily focusing on neuroregeneration, peripheral nerve repair, cardiac protection, anti-aging. Typical research protocols investigate administering 5000 to 10000mcg via subq pathways daily x 10 days. However, it is critically important to understand that while Cortagen demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.